增强的多模式低级嵌入式特征选择模型用于多模式阿尔茨海默氏病诊断
IEEE transactions on medical imaging
|September 20, 2024
概括
本研究介绍了使用神经成像数据进行阿尔茨海默病 (AD) 诊断的增强多式低级嵌入 (EMLE). EMLE有效地选择特征,并增强对受损数据的稳定性,以改进AD识别.
科学领域:
- 神经成像是一种神经成像.
- 医学诊断 医学诊断 医学诊断
- 机器学习 机器学习
背景情况:
- 多模式神经成像数据有助于阿尔茨海默病 (AD) 的识别.
- 冗余的功能和受损的数据挑战了现有的诊断方法.
研究的目的:
- 提议增强多模式低级嵌入 (EMLE) 进行强大的AD诊断.
- 共同嵌入功能,并选择每个模式的信息功能.
主要方法:
- 使用L1-规范规范化的投影矩阵与最小形惩罚 (MCP) 进行特征选择.
- 学习使用自我表达力的相似度图,以了解数据腐败的稳定性.
- 通过MCP应用矩阵L0-norm来限制图表排名.
- 建立跨模式的共识图表,以揭示共享的AD相关结构.
- 保险丝嵌入式表示与监管信息进行分类.
主要成果:
- 埃梅尔有效地从多式联络神经成像数据中选择歧视性特征.
- 该方法证明了对损坏的神经图像的稳定性.
- 阿尔茨海默病神经成像计划数据集的实验结果验证了EMLE的表现.
结论:
- EMLE提供了一种强大的方法来诊断阿尔茨海默病,使用多模式神经成像.
- 拟议的方法增强了特征选择和数据完整性,以提高诊断准确度.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170